BlackRock Advisors’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$411M Buy
1,448,464
+257,964
+22% +$76.5M 0.42% 52
2016
Q3
$373M Buy
1,190,500
+128,533
+12% +$38.1M 0.38% 61
2016
Q2
$257M Sell
1,061,967
-8,080
-0.8% -$2.13M 0.26% 94
2016
Q1
$279M Sell
1,070,047
-286,524
-21% -$75.7M 0.29% 83
2015
Q4
$416M Sell
1,356,571
-202,049
-13% -$58.1M 0.44% 56
2015
Q3
$455M Buy
1,558,620
+755,770
+94% +$250M 0.49% 42
2015
Q2
$324M Buy
802,850
+77,722
+11% +$31.2M 0.34% 81
2015
Q1
$306M Sell
725,128
-55,059
-7% -$21.7M 0.31% 83
2014
Q4
$265M Sell
780,187
-745,660
-49% -$241M 0.27% 97
2014
Q3
$505M Sell
1,525,847
-274,019
-15% -$90.4M 0.5% 46
2014
Q2
$568M Buy
1,799,866
+339,384
+23% +$102M 0.54% 40
2014
Q1
$447M Buy
1,460,482
+468,965
+47% +$149M 0.44% 51
2013
Q4
$277M Buy
991,517
+11,411
+1% +$2.95M 0.27% 93
2013
Q3
$236M Buy
980,106
+155,331
+19% +$34.8M 0.24% 109
2013
Q2
$177M Buy
+824,775
New +$176M 0.19% 131

Other funds holding BIIB

BlackRock Advisors's BIIB Position: Q4 2016 in Review

BlackRock Advisors increased its Biogen (BIIB) stake by 22% in Q4 2016, buying an estimated $76.5M and bringing the position to 1,448,464 shares worth $411M. The position accounts for 0.42% of the portfolio, ranked #52.

BlackRock Advisors first reported a position in BIIB in Q2 2013 and has held it in 15 quarters since. The position peaked at $568M in Q2 2014. 1,025 funds tracked by Wall St. Rank hold BIIB as of Q4 2016.

  • BlackRock Advisors held 1,448,464 shares of Biogen worth $411M as of Q4 2016.
  • BlackRock Advisors bought 257,964 Biogen shares in Q4 2016, an estimated $76.5M.
  • Biogen made up 0.42% of BlackRock Advisors's portfolio in Q4 2016, its #52 holding.
  • BlackRock Advisors first reported a position in Biogen in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Biogen position peaked at $568M in Q2 2014.
  • 1,025 funds tracked by Wall St. Rank held Biogen as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.